跳至主要内容
临床试验/NCT00137332
NCT00137332终止2 期

A Study of the Effects GAP-486 on Ventricular Tachyarrhythmia Induction

Wyeth is now a wholly owned subsidiary of Pfizer33 个研究点 分布在 2 个国家目标入组 90 人开始时间: 2005年11月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
发起方
入组人数
90
试验地点
33
主要终点
The measure to determine the effect of the intervention will be whether abnormally fast heart rhythm can be induced after test drug is administered.

研究概览

简要总结

The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients with or without ICDs (implantable cardioverter defibrillators)
  • •Patients undergoing an electrophysiology study for evaluation of ventricular rhythm
  • •Patients with a history of heart disease

排除标准

  • •Patients with uncontrolled blood pressure
  • •Patients with certain cardiac risk factors
  • •Patients with significant kidney or liver problems

结局指标

主要结局

The measure to determine the effect of the intervention will be whether abnormally fast heart rhythm can be induced after test drug is administered.

次要结局

  • This study takes place within 24 hours, and looks at whether the test article makes a difference in inducing the abnormally fast heart rhythm during a 24 hour observational period.

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

研究点 (33)

Loading locations...

相似试验